Schrodinger Inc
NASDAQ:SDGR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.98
37.21
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Schrodinger Inc
Schrodinger Inc
Total Liabilities & Equity
Schrodinger Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Schrodinger Inc
NASDAQ:SDGR
|
Total Liabilities & Equity
$669.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Total Liabilities & Equity
$6.5B
|
CAGR 3-Years
24%
|
CAGR 5-Years
28%
|
CAGR 10-Years
29%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Total Liabilities & Equity
$796.2m
|
CAGR 3-Years
42%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Total Liabilities & Equity
$1.1B
|
CAGR 3-Years
62%
|
CAGR 5-Years
66%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Total Liabilities & Equity
$2.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Total Liabilities & Equity
$4.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Schrodinger Inc
Glance View
In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry. Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.
See Also
What is Schrodinger Inc's Total Liabilities & Equity?
Total Liabilities & Equity
669.3m
USD
Based on the financial report for Sep 30, 2024, Schrodinger Inc's Total Liabilities & Equity amounts to 669.3m USD.
What is Schrodinger Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
34%
Over the last year, the Total Liabilities & Equity growth was -16%. The average annual Total Liabilities & Equity growth rates for Schrodinger Inc have been -4% over the past three years , 34% over the past five years .
You don't have any saved screeners yet
